Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial

贝伐单抗 医学 化疗 内科学 危险系数 肿瘤科 耐受性 卵巢癌 随机对照试验 卡铂 外科 癌症 不利影响 置信区间 顺铂
作者
Aris Bamias,Emma Gibbs,Chee Khoon Lee,Lucy Claire Davies,Meletios Athanasios Dimopoulos,Flora Zagouri,Anne-Sophie Veillard,Jens Kosse,Ana Santaballa,Mansoor Raza Mirza,Gianna Tabaro,Ignace B. Vergote,Haiko J. Bloemendal,Maria Lykka,Anne Floquet,Val Gebski,Éric Pujade-Lauraine
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:28 (8): 1842-1848 被引量:60
标识
DOI:10.1093/annonc/mdx228
摘要

In the open-label randomized phase III AURELIA trial, adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer (PROC) significantly improved progression-free survival and response rate versus chemotherapy alone, but not overall survival (OS). We explored the effect of bevacizumab use after disease progression (PD) in patients randomized to chemotherapy alone.In AURELIA, 361 women with PROC were randomized to chemotherapy alone or with bevacizumab. Patients initially randomized to chemotherapy were offered bevacizumab after PD. Post hoc analyses assessed efficacy and safety in three subgroups: chemotherapy alone, chemotherapy followed by bevacizumab after PD, and chemotherapy plus bevacizumab at randomization.Of the 182 patients randomized to chemotherapy alone, 72 (40%) received bevacizumab after PD and 110 (60%) never received bevacizumab. There were no significant differences in patient and disease characteristics between these subgroups at baseline or the time of PD. Compared with patients never receiving bevacizumab, the risk of death was significantly reduced in patients receiving bevacizumab either upfront with chemotherapy [hazard ratio (HR) = 0.68, 95% confidence interval (CI) 0.52-0.90] or after PD (HR = 0.60, 95% CI 0.43-0.86). The tolerability of bevacizumab was similar with administration upfront or after PD.Post-PD bevacizumab use may have confounded OS results in AURELIA. In these exploratory analyses of non-randomized subgroups, bevacizumab use, either with chemotherapy or after PD on chemotherapy alone, improved OS compared with no bevacizumab. Combining bevacizumab with chemotherapy at first appearance of platinum resistance maximises the likelihood of patients receiving this active treatment for PROC. ClinicalTrials.gov: NCT00976911.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
光亮的天与完成签到,获得积分10
刚刚
知识进脑子吧完成签到 ,获得积分10
刚刚
喜悦的铭完成签到,获得积分10
刚刚
犹豫的若男完成签到,获得积分10
1秒前
dawner完成签到,获得积分10
1秒前
彭于晏的应助被伯赏迎松采纳,获得10
1秒前
可爱的函函的应助被赤练仙子采纳,获得10
1秒前
1秒前
幸福的襄完成签到,获得积分20
1秒前
1秒前
铎铎铎发布了新的文献求助10
2秒前
慕青的应助被吾吾采纳,获得10
2秒前
2秒前
3秒前
糖糖糖86完成签到,获得积分10
3秒前
cc03完成签到,获得积分10
3秒前
我是谁的应助被天天采纳,获得20
3秒前
我是谁的应助被天天采纳,获得20
3秒前
内向百川发布了新的文献求助10
3秒前
我是谁的应助被天天采纳,获得20
3秒前
我是谁的应助被天天采纳,获得20
3秒前
3秒前
哈哈哈完成签到,获得积分10
4秒前
睡一觉算了完成签到,获得积分10
4秒前
4秒前
陶醉的念之完成签到,获得积分10
4秒前
灵巧的念烟完成签到,获得积分10
4秒前
4秒前
Liujun完成签到,获得积分10
4秒前
幸福的襄发布了新的文献求助10
4秒前
4秒前
5秒前
5秒前
5秒前
5秒前
务实寒烟完成签到,获得积分10
6秒前
舒心的荟完成签到 ,获得积分10
6秒前
上官若男的应助被星空采纳,获得10
6秒前
zhao完成签到 ,获得积分10
6秒前
背锅侠发布了新的文献求助10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180407
求助须知:如何正确求助?哪些是违规求助? 9570403
关于积分的说明 21811831
捐赠科研通 7776452
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557499
邀请新用户注册赠送积分活动 2479105